IL23R
IL23R is a critical component of the receptor for IL-23, the primary "fuel" for Th17 cell survival and expansion. Genetic variants in IL23R are strongly associated with protection or susceptibility to major inflammatory diseases like Crohn’s and psoriasis.
Key Takeaways
- •IL23R is the essential "antenna" that allows immune cells to respond to IL-23.
- •It is the primary regulator of Th17 cell survival and their production of tissue-destroying cytokines.
- •The R381Q variant (rs11209026) is a famous "protective" mutation that slashes the risk of Crohn’s and psoriasis.
- •Blocking the IL-23/IL-23R axis is the mechanism of action for the most effective modern treatments for psoriasis.
Basic Information
- Gene Symbol
- IL23R
- Full Name
- Interleukin 23 Receptor
- Location
- 1p31.3
- Protein Type
- Cytokine Receptor Subunit
- Protein Family
- Interleukin-23 receptor
Related Isoforms
Key SNPs
A rare example of a highly protective variant; the Gln381 allele reduces the risk of Crohn’s disease by ~3-fold and also protects against psoriasis and ankylosing spondylitis.
A frequent variant associated with increased IL23R expression and higher susceptibility to inflammatory bowel disease.
Common marker used in GWAS panels to identify the 1p31 risk locus for diverse autoimmune conditions.
Overview
IL23R encodes the specific subunit of the receptor for Interleukin-23 (IL-23). While naive T-cells do not express this receptor, it is rapidly upregulated on T-helper cells after they have been "primed" toward the Th17 lineage. Because of this, IL23R acts as a highly specific gatekeeper that controls the activity of the body’s most aggressive pro-inflammatory cells.
The IL-23/IL23R pathway is often called the "fuel" of the Th17 response. While other cytokines create Th17 cells, IL-23 is required to keep them alive and instructed to attack. Dysregulation of this receptor leads to the "runaway" inflammation seen in autoimmune diseases of the skin, gut, and joints. Conversely, natural genetic variants that dampen IL23R signaling provide some of the strongest protection against autoimmunity known in human genetics.
Conceptual Model
A simplified mental model for the pathway:
IL23R ensures that Th17 cells only "burn" when a serious threat is detected.
Core Health Impacts
- • Th17 Maintenance: Required for the long-term survival and pathogenic expansion of Th17 cells
- • Mucosal Defense: Promotes the production of IL-22 to maintain barrier integrity in the gut and skin
- • Inflammatory Amplification: Drives the sustained production of IL-17A and IL-17F in target tissues
- • Osteoclast Activation: Indirectly promotes bone resorption in inflammatory arthritis via RANKL induction
- • Vascular Inflammation: Contributes to the systemic inflammatory tone that accelerates cardiovascular aging
Protein Domains
Extracellular Domain
Specifically binds the p19 subunit of the IL-23 cytokine with high affinity.
Transmembrane Helix
Anchors the receptor in the membrane and transmits the binding signal into the cell.
Intracellular Tail
Recruits JAK2 and STAT3; the R381Q protective variant is located in this signaling domain.
Upstream Regulators
IL-23 Activator
The definitive ligand; produced by dendritic cells and macrophages to fuel Th17 activity.
STAT3 Activator
Transcription factor that binds to the IL23R promoter to upregulate its expression in T-cells.
RORγt Activator
The master lineage-defining factor for Th17 cells that makes the cell "ready" to express IL23R.
Th17 Cells Activator
The primary cell type that expresses functional IL23R complexes on its surface.
ILC3s Activator
Innate lymphoid cells that use IL23R to sense IL-23 and produce barrier-healing IL-22.
Downstream Targets
JAK2 / TYK2 Activates
Receptor-associated kinases that phosphorylate and activate the signaling cascade.
STAT3 Activates
The primary transcription factor activated by IL23R; drives the production of Th17 effector genes.
IL-17A / IL-17F Activates
The "weapons" of the Th17 cell, whose long-term production is dependent on IL23R signaling.
IL-22 Activates
A cytokine essential for tissue repair and defense, upregulated by IL-23 in both T-cells and ILCs.
Th17 Survival / Expansion Activates
The definitive outcome of IL23R signaling; prevents the programmed death of inflammatory cells.
Role in Aging
The IL-23/IL23R axis is a major contributor to the age-related shift toward a pro-inflammatory state. As visceral fat and cellular senescence increase, the baseline "noise" of the immune system favors the expansion of IL23R-positive cells, driving chronic low-grade tissue damage.
Pathogenic Expansion
Older immune systems accumulate "memory" Th17 cells that rely on IL23R for persistence, creating a durable pool of inflammatory potential.
Osteoimmunology
Age-related increases in IL23R signaling promote bone loss by tipping the balance toward osteoclast (bone-dissolving) activity.
Vascular Remodeling
The IL-23 axis promotes the arterial stiffening and endothelial dysfunction characteristic of cardiovascular aging.
Barrier Failure
Chronic over-stimulation of IL23R can lead to the exhaustion of barrier-maintaining ILC3 cells in the gut and lungs.
Senescence Synergy
IL-23 can amplify the Senescence-Associated Secretory Phenotype (SASP), turning local senescence into a broader inflammatory event.
Neuroinflammation
IL23R-positive cells infiltrate the aging brain, where they contribute to the neuroinflammatory environment of cognitive decline.
Disorders & Diseases
Psoriasis
The most responsive disease to IL-23 inhibition. IL23R signaling drives the skin inflammation and plaques of moderate-to-severe psoriasis.
Crohn’s Disease
IL23R is a primary driver of the transmural inflammation in Crohn’s. Genetic variants determine disease severity and location (ileal vs colonic).
Ankylosing Spondylitis
The IL-23 pathway is essential for the entheseal inflammation and pathological bone formation seen in this spinal arthritis.
Ulcerative Colitis
Like Crohn’s, UC involves dysregulated IL23R signaling, though the protective effect of certain SNPs is even more pronounced here.
Psoriatic Arthritis
The extension of the IL-23/Th17 axis from the skin to the joints, leading to pain, swelling, and structural damage.
The R381Q Protective Shield
Carrying the Arg381Gln variant is like having a natural "dose" of an IL-23 inhibitor. These individuals produce a slightly less stable receptor that limits Th17 expansion, protecting them from a wide range of autoimmune triggers.
Interventions
Supplements
Polyphenol studied for its ability to modulate the STAT3 signaling pathway downstream of IL23R.
Sirtuin activator reported to influence Th17 cell differentiation and potentially dampen IL-23 responsiveness.
Essential for maintaining the balance between Th17 and Treg cells; deficiency is linked to hyper-active IL-23 signaling.
Traditional anti-inflammatory reported to inhibit pro-inflammatory cytokine pathways including the IL-23 axis.
Lifestyle
Reducing processed sugars and trans-fats lowers the metabolic "priming" that favors Th17 expansion.
Chronic stress-induced cortisol dysregulation can lead to a "rebound" Th17 state with increased IL23R expression.
Supports Vitamin D production, a critical negative regulator of the pathogenic IL-23/IL-17 axis.
A healthy gut microbiome prevents the "leaky" state that provides the bacterial stimuli for IL-23 production.
Medicines
Monoclonal antibody that binds specifically to the p19 subunit of IL-23, preventing its interaction with IL23R.
High-affinity IL-23p19 inhibitor; currently among the most effective treatments for clearing psoriasis.
Blocks the p40 subunit shared by both IL-12 and IL-23; effective in Crohn’s and psoriasis.
Small molecules that block the signaling kinases directly attached to the IL23R intracellular tail.
Lab Tests & Biomarkers
Genetic Screening
Testing for the R381Q variant to identify individuals with high natural protection against Crohn’s and psoriasis.
Combines IL23R with other markers (HLA-B27, NOD2) to provide a comprehensive autoimmune profile.
Inflammatory Markers
Can be measured but often reflect local tissue activity rather than systemic state; used primarily in research.
Systemic marker of inflammation that tracks with the activity of the IL-23/IL-17 axis in chronic disease.
Biopsy Assays
Assessed via flow cytometry in tissue samples; identifies the density of IL23R-positive cells in skin or gut.
Direct marker of active signaling through the IL23R complex in biopsy samples.
Hormonal Interactions
Estrogen Modulator
Influences Th17/Treg balance; shifts during menopause can impact the activity of the IL-23 axis.
Cortisol Inhibitor
Glucocorticoids are potent suppressors of the dendritic cells that produce the IL-23 ligand.
Melatonin Modulator
Reported to regulate RORγt activity, indirectly impacting the expression of the IL23R receptor.
Leptin Activator
Adipose-derived hormone that promotes Th17 differentiation and upregulates IL23R in obesity.
Deep Dive
Network Diagrams
The IL-23 Receptor Complex
The Antenna of Autoimmunity: How IL23R Fuels Th17 Cells
To understand IL23R, one must distinguish between the “birth” and the “life” of an inflammatory T-cell. While cytokines like TGF-beta and IL-6 tell a naive T-cell to become a Th17 cell, it is IL-23 that allows those cells to survive, multiply, and become tissue-destroying agents.
The Functional Antenna: The IL23R complex is a heterodimer—it requires two different proteins to work. It consists of the specific IL23R subunit and a shared subunit called IL12RB1. Together, they form the functional antenna that captures IL-23 from the extracellular space.
The Pro-survival Signal: When IL-23 binds, it triggers the recruitment of JAK2 and TYK2 kinases. These kinases “flip the switch” on STAT3, which enters the nucleus and turns on genes that prevent the cell from dying. This is why IL-23 is called the “survival factor” for Th17 cells—without IL23R signaling, these aggressive cells would simply wither away.
The Protective Paradox: rs11209026 (R381Q)
Human genetics rarely provides such a clear-cut example of a single mutation providing massive protection against chronic disease as the rs11209026 (Arg381Gln) variant in IL23R.
The Mechanism of Protection: The substitution of Glutamine (Q) for Arginine (R) at position 381 occurs in the intracellular signaling tail of the receptor. This change makes the receptor slightly less stable and less efficient at recruiting the signaling kinases.
The Clinical Shield: Because the signal is dampened, Th17 cells in these individuals do not expand as aggressively. The result is a profound “shield” against autoimmunity: carriers of the Q allele have a 3-fold lower risk of Crohn’s disease and are similarly protected against psoriasis and ankylosing spondylitis. This variant is one of the premier targets for researchers looking to design drugs that mimic natural genetic health.
Psoriasis: The Success Story of IL-23 Blockade
Nowhere is the importance of IL23R more evident than in the treatment of psoriasis. For decades, psoriasis was treated with broad immunosuppressants that had severe side effects.
The Th17 Revolution: Once the IL-23/IL23R axis was identified as the master controller of Th17 cells, pharmaceutical companies developed monoclonal antibodies (like Guselkumab and Risankizumab) that specifically block IL-23 from binding to its receptor.
Precision Clearance: These “p19 inhibitors” have revolutionized dermatology. Because they only target the “pathogenic” arm of the immune system (Th17 survival) and leave the rest of the immune system intact, they can clear skin plaques almost completely in over 80% of patients with very few side effects. This success has proven that the IL23R receptor is the definitive therapeutic “hub” for modern immunology.
Practical Note: Genetics and Drug Response
Protective doesn't mean immune. While the R381Q variant slashes risk, it does not guarantee a person will never develop Crohn’s or psoriasis. However, it often predicts a "milder" disease course if it does occur.
Targeting the Fuel. Modern "p19" inhibitors (Guselkumab, Risankizumab) are the most precise way to hit this pathway because they only block IL-23, leaving the IL-12 pathway (which is essential for cancer defense) intact.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark discovery of the IL23R locus and the identification of the highly protective R381Q variant in IBD.
Pivotal study distinguishing the role of IL-23 (autoimmunity) from IL-12 (protective immunity).
Characterized the central role of IL23R-positive cells in the skin lesions of psoriasis patients.
Clinical trial proving that blocking the intracellular signaling of IL23R is a highly effective therapeutic strategy.
The VOYAGE 1 trial results establishing IL-23 blockade as a superior class of therapy for moderate-to-severe psoriasis.